Massive study pits popular Weight-Loss drugs against each other for heart protection
NCT ID NCT07096063
Summary
This study analyzed health insurance records for nearly 900,000 people to see how newer diabetes and weight-loss medications compare for preventing heart attacks and strokes. It focused on adults with type 2 diabetes, overweight, and existing heart disease risk. The goal was to understand which drug—tirzepatide or semaglutide—might offer better real-world protection against serious heart problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.